Teva and Eagle Pharmaceuticals Announce Teva's License to Commercialize … – MarketWatch

Teva and Eagle Pharmaceuticals Announce Teva's License to Commercialize …MarketWatchEagle has requested Priority Review of the NDA; this product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval. … The most common non-blood …and more »